## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.47 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($340.80)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Stryker stock slips today as year-end trading turns cautious â€” dividend date and new COO in focus**
- Source: ts2.tech | 20251230T041113 | Somewhat-Bearish | Relevance: 100%
- Stryker (SYK) shares closed down 0.5% in cautious year-end trading, with investors focused on a December 31st dividend record date and a January 1st leadership change as Spencer Stiles becomes President and COO. The stock is holding near a $350 support level, and the company has declared a quarterly dividend of $0.88 per share. The broader market also saw a pullback in the final week of 2025.

**2. Ascent Group LLC Increases Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251231T084735 | Bullish | Relevance: 100%
- Ascent Group LLC significantly increased its stake in Stryker Corporation by 124.4% in Q3, now owning 13,038 shares valued at approximately $4.82 million. This comes as Stryker reported strong quarterly earnings, exceeding EPS expectations and increasing its dividend, despite recent large insider selling activity. Institutional investors currently hold about 77.09% of the medical technology company's stock, while analysts maintain a "Moderate Buy" consensus rating.

**3. Norris Perne & French LLP MI Has $16.69 Million Stock Holdings in Stryker Corporation $SYK**
- Source: MarketBeat | 20251229T123036 | Somewhat-Bullish | Relevance: 100%
- Norris Perne & French LLP MI significantly increased its stake in Stryker Corporation by 157.5% in Q3, now holding 45,153 shares valued at approximately $16.69 million. Despite institutional ownership reaching 77.09% and a "Moderate Buy" consensus rating from analysts, company insiders have recently sold a substantial volume of shares. Stryker also raised its quarterly dividend to $0.88, resulting in a 1.0% annualized yield.

**4. Pacer Advisors Inc. Decreases Stock Position in Stryker Corporation $SYK**
- Source: MarketBeat | 20251229T104807 | Neutral | Relevance: 100%
- Pacer Advisors Inc. reduced its stake in Stryker Corporation by 11.6% in the third quarter of 2025, selling 3,650 shares and retaining 27,768 shares valued at approximately $10.27 million. This move comes amidst significant insider selling, with Director Ronda E. Stryker selling 276,173 shares and total insider sales reaching over $185 million in the past 90 days. Wall Street maintains a "Moderate Buy" rating for Stryker, with an average price target of $431.84, while the company recently increased its quarterly dividend to $0.88 per share.

**5. Boston Trust Walden Corp Reduces Position in Stryker Corporation $SYK**
- Source: MarketBeat | 20251229T095149 | Neutral | Relevance: 100%
- Boston Trust Walden Corp reduced its stake in Stryker Corporation by 7.1% in the third quarter, holding 287,909 shares valued at $106.4 million. This move coincides with significant insider selling, where insiders offloaded over 522,000 shares worth $185.4 million in the last 90 days. Despite this, analysts maintain a "Moderate Buy" rating for Stryker, with the company beating recent earnings estimates and increasing its quarterly dividend.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Citizens | $440 | $0 | 0% |
| 2025-12-18 | Truist Securiti | $392 | $400 | -2% |
| 2025-12-11 | Citigroup | $420 | $455 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Citizens | up | Market Outperform |
| 2025-12-18 | Truist Securiti | main | Hold |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.76M) |
| Sells | 7 ($21.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $21M sold (7 transactions in 90 days).
2. Long-term trend broken: trading 6.2% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 23.5x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Analyst sentiment negative (2 target cuts vs 0 raises). Insider selling cluster ($21.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $134.4B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 23.5 |
| Current P/E | 25.9 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.2% to -0.5% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.5pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 40. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.45% (CS: 40) | Neutral |
| RSI_14 | 40.2 | Neutral |
| MACD Histogram | 0.17 | Bullish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 0.969x | Below |
| vs SMA200 | 0.938x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $351.54
- **Stop Loss:** $340.80 (3.1% risk)
- **Target:** $373.02 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 134
- **Position Value:** $47,106.36
- **Portfolio %:** 47.11%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*